MBX Biosciences backed BIO’s Fight Of Our Lives campaign, underscoring the push for new chronic disease treatments as 194 million Americans live with long-term

MBX Biosciences backed BIO’s Fight Of Our Lives campaign, underscoring the push for new chronic disease treatments as 194 million Americans live with long-term conditions. The company is also expanding work on obesity and hypoparathyroidism therapies.